Facebook
Linkedin
Twitter
Industries
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Resource Center
Resources
Press Releases
Search
Tuesday, November 5, 2024
Facebook
Linkedin
Twitter
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
ReadMagazine
Industries
All
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Resilinc Announces Chris Lanier as New Chief Technology Officer
SkySafe and Fortem Partner to Enhance Drone Detection and Mitigation
Cequence Security and AWS Team Up for Advanced API Protection and…
PCS Software Appoints Danielle Villegas as Chief Product Officer
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Resource Center
Resources
Press Releases
Home
Tags
ICH Treatment
ICH Treatment
Biotechnology
ClearMind Biomedical Clears FIM Clinical Trial for Least Invasive ICH Treatment to Date
PR Newswire
-
July 6, 2022
ClearMind Biomedical's novel neurosurgical endoscope, the Axonpen System, has completed its First in Man (FIM) clinical trial in Taiwan with outstanding results. The Axonpen System...
0
Fans
Like
3,912
Followers
Follow
0
Subscribers
Subscribe
Hot Topics
Resilinc Announces Chris Lanier as New Chief Technology Officer
SkySafe and Fortem Partner to Enhance Drone Detection and Mitigation
Cequence Security and AWS Team Up for Advanced API Protection and Bot Management
Load more
